Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arbutus Biopharma Corp ABUS

Healthcare Biotechnology
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran... see more

Recent & Breaking News (NDAQ:ABUS)

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Business Wire December 3, 2024

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

GlobeNewswire November 26, 2024

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

GlobeNewswire November 15, 2024

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

GlobeNewswire November 15, 2024

Arbutus to Present at Jefferies London Healthcare Conference

GlobeNewswire November 14, 2024

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2024

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

GlobeNewswire October 23, 2024

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

GlobeNewswire October 15, 2024

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

GlobeNewswire October 1, 2024

Arbutus to Participate in Two Upcoming Investor Conferences

GlobeNewswire September 3, 2024

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 1, 2024

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

GlobeNewswire July 18, 2024

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

GlobeNewswire June 6, 2024

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

GlobeNewswire June 6, 2024

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

GlobeNewswire June 5, 2024

Arbutus to Participate in Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2024

Arbutus to Present Imdusiran Data at EASL Congress 2024

GlobeNewswire May 22, 2024

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Business Wire May 17, 2024

Arbutus to Participate in Two Upcoming Investor Conferences

GlobeNewswire May 7, 2024

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 2, 2024